Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to solicit grant applications that propose to establish Consortia for HIV/AIDS Vaccine Development (CHAVD) to support a coordinated, multidisciplinary team(s) of researchers focused on iterative approaches to accelerate HIV vaccine development by addressing key immunogen design roadblocks to the discovery and development of a safe and effective antibody-mediated preventive HIV vaccine.

The purpose of this funding opportunity is to conduct activities to promote and support vaccination services within the pharmacy setting. Activities include, but are not limited to: - Education/Outreach to pharmacists about current pediatric, adolescent, and adult immunization recommendations and proper vaccine administration - Facilitation of communication and exchange of information between pharmacists and providers and public health programs -Quality Improvement efforts -Improved immunization documentation through use of immunization information systems and data sharing -Coordination with public health preparedness and immunization programs to establish formalized agreements for pandemic vaccine program readiness and response By the end of the project, the awardee is expected to disseminate and promote best practices/successes to a national audience of healthcare providers, including both pharmacists and other healthcare providers.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on establishing proof-of-concept for and/or preclinical development of lead candidate vaccines targeting infection with Mycobacterium tuberculosis (Mtb) and/or tuberculosis disease (TB).

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on establishing proof-of-concept for and/or preclinical development of lead candidate vaccines targeting infection with Mycobacterium tuberculosis (Mtb) and/or tuberculosis disease (TB).

BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of Chemical, Biological, Radiological and Nuclear (CBRN) agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the 2014 PHEMCE Implementation Plan for CBRN Threats. 

TRANSLATIONAL MEDICINE AND THERAPEUTICS: The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation: "Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to use clinical observation as the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients." Translational Medicine and Therapeutics awards will advance training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to): * Genetics (Molecular, Pharmaco-, Population, Medical) * Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative) * Systems (Biology and Pharmacology) * Pathways and networks * Integrative biology * Modeling and simulation * Target Identification and Validation * Biomarker Discovery and Validation * Vaccine Development * Molecular Epidimiology * Imaging * Disease Modeling

The purpose of this Broad Agency Announcement (BAA) is to solicit research proposals for Chemical and Biological Defense Program (CBDP), Defense Threat Reduction Agency (DTRA) requirements for the CBDP Ebola BAA for the FY2015-2016 program. DTRA, with industry and government partners, has been working aggressively for the past decade to understand and counter Zaire ebolavirus (EBOV). DTRA's program is currently supporting the accelerated development of a therapeutic through preclinical Investigational New Drug (IND) enabling activities as well as the clinical evaluation for one EBOV vaccine. The program co-developed the rapid field deployable diagnostic systems currently in use in West Africa. The program has also been adapting and improving upon North Atlantic Treaty Organization (NATO) approved and high performance computing methods of modeling EBOV to perform analysis of the current EBOV outbreak. Recognizing that industry may have solutions applicable to the current EBOV outbreak in West Africa, this BAA has been released to ensure that all potential near-term solutions are considered.

This Funding Opportunity Announcement (FOA) invites applications from institutions and organizations to conduct research focused on elucidating mechanisms of Fc-dependent, antibody-mediated killing of infected or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. Studies supported by this FOA are expected to define variables that affect efficiencies of antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosis (ADCP), both in vitro and in vivo. U01 awardees will be expected to attend annual Program Progress/Steering Committee meetings and present progress to fellow awardees and to NIAID program staff. The goal of the meetings is to facilitate collaborations between funded investigators and to accelerate development of mechanistic models that incorporate the collective findings of this program. Advances in our understanding of these Fc-dependent killing mechanisms will inform more efficient design and optimization of ablative antibody therapeutics and may also inform design of vaccines that preferentially elicit ADCC- or ADCP-efficient antibody responses. This FOA uses the U01 grant mechanism, while the companion FOA, PA-19-xxx, uses the R21 mechanism. High risk/high reward projects with limited preliminary data or utilize existing data may be most appropriate for the R21 mechanism.

WHO CAN APPLY? I-Corps@Ohio funds will be offered on a competitive basis to teams of faculty researchers and graduate students developing institution-based technologies from Ohio colleges and universities. Under the supervision of business and entrepreneurial mentors, teams will develop market-driven value propositions and scalable business models around their technologies and attract follow on funding to support company formation and market entry. APPLICATION PROCESS The I-Corps@Ohio proposal submission process consists of five steps: 1. mandatory meeting with the appropriate TTO representative(s) at the PI's institution; 2. team selection of technology track (science and engineering or medtech); 3. registration of all team members in the online portal; 4. proposal submission; and 5. full team interview with I-Corps@Ohio program representatives. All teams are required to complete the online profile and submission questionnaire beginning October 23, 2019. Deadline to apply is January 15, 2019. The PI may complete this information or designate another member of the team as the lead member. Subsequent members of the team will be invited to join by the lead member through the application portal and must complete his or her profile. Every effort should be made to identify all team members prior to submitting the online proposal submission questionnaire. Additional team members may be added later. You will be asked to select from two tracks: Medtech Track: Teams will select Medtech Track if the subject technology is in the form of medical devices, diagnostics, medicines, vaccines, software, testing procedures and systems and is developed to solve a health/clinical problem and improve the quality of human life. Science and Engineering (S&E) Track: Teams will select S&E Track if the technology does not fit into the Medtech category.